Ovid Therapeutics Announces Positive Topline Results from the Phase 2 ROCKET Trial of OV101 for the Treatment of Fragile X Syndrome

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access